Skip to main content
. Author manuscript; available in PMC: 2018 Apr 21.
Published in final edited form as: J Mol Biol. 2017 Mar 11;429(8):1114–1142. doi: 10.1016/j.jmb.2017.03.005

Table 3.

Clinical trials with MAGEs

MAGE Tumor type Phase Intervention Identifier Status
A3 Melanoma I/II MAGE-A3.A1 peptide and CpG7909 NCT00145145 Terminated
A3 Melanoma II GSK1203486A recombinant MAGE-A3
ASCI
NCT00706238 Terminated
A3 Melanoma II GSK2132231A, dacarbazine NCT00849875 Terminated
A3 Melanoma III GSK 2132231A NCT00796445 Terminated
A3 Lung I GSK1572932A, cisplatin, vinorelbine, radiotherapy NCT00455572 Terminated
A3 Lung III GSK1572932A NCT00480025 Terminated
A3, A12 Metastatic I/II anti-MAGE-A3/12 TCR, aldesleukin, cyclophosphamide, fludarabine NCT01273181 Terminated
A3 Melanoma I/II Enhanced TCR Transduced Autologous T Cells NCT01350401 Ongoing
A3 Multiple myeloma I/II Enhanced TCR Transduced Autologous T Cells NCT01352286 Ongoing
A3, C2 Melanoma II TriMix-DC and ipilimumab NCT01302496 Ongoing
A3, C1 Multiple myeloma I CT7, MAGE-A3, and WT1 mRNA- electroporated Langerhans cells (LCs) NCT01995708 Recruiting
A3 Metastatic I/II Anti-MAGE-A3-DP4 TCR, cyclophosphamide, fludarabine, aldesleukin NCT02111850 Recruiting
A3 Metastatic I/II MG1MA3 (MG1 Maraba/MAGE-A3 adenovirus vaccine) NCT02285816 Recruiting
A10 Urinary bladder, head and neck, melanoma I Autologous genetically modified MAGE A10C796T cells NCT02989064 Recruiting
A10 Lung I/II Autologous genetically modified MAGE A10C796T cells NCT02592577 Recruiting
A3 Lung I/II Ad-MAGEA3, MG1-MAGEA3, pembrolizumab NCT02879760 Recruiting